0000000000272106

AUTHOR

Myriam Meineck

showing 11 related works from this author

Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants

2016

Background: Alzheimer’s disease is one of the most prevalent dementias in the elderly population with increasing numbers of patients. One pivotal hallmark of this disorder is the deposition of protein aggregates stemming from neurotoxic amyloid-beta peptides. Synthesis of those peptides has been efficiently prevented in AD model mice by activation of an enzyme called alpha-secretase. Therefore, drugs with the capability to increase the expression of this enzyme, named ADAM10, have been suggested as a valuable therapeutic medication. Methods: We investigated 69 substances from a drug library derived from traditional Chinese medicine by luciferase reporter assay in human neuronal cells for th…

0301 basic medicinePhlogacanthus curviflorusADAM10lcsh:MedicineProtein aggregationBiologyPharmacologyArticle03 medical and health sciences0302 clinical medicineWestern blotGene expressionPhlogacantholide CmedicineAmyloid precursor proteinSecretionEnhancerADAM10; Amyloid precursor protein; Alzheimer’s disease; Norkurarinol; Phlogacantholide C; <i>Phlogacanthus curviflorus</i>; <i>Sophora flavescens</i>chemistry.chemical_classificationmedicine.diagnostic_testlcsh:RADAM10Norkurarinol030104 developmental biologyEnzymechemistrySophora flavescensAmyloid precursor proteinbiology.proteinAlzheimer’s disease030217 neurology & neurosurgeryMedicines
researchProduct

IL-34–Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice

2019

Background In people with SLE and in the MRL- Fas lpr lupus mouse model, macrophages and autoantibodies are central to lupus nephritis. IL-34 mediates macrophage survival and proliferation, is expressed by tubular epithelial cells (TECs), and binds to the cFMS receptor on macrophages and to a newly identified second receptor, PTPRZ. Methods To investigate whether IL-34–dependent intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL- Fas lpr mice expressing IL-34 and IL-34 knockout (KO) MRL- Fas lpr mice. We also assessed expression of IL-34 and the cFMS and PTPRZ receptors in patients with lupus nephritis. Results Intrarenal IL-3…

0301 basic medicineMice Inbred MRL lprChemokineCell SurvivalLupus nephritisRisk AssessmentMonocytesMice03 medical and health sciences0302 clinical medicineSpecies Specificityimmune system diseasesmedicineAnimalsMacrophageMolecular Targeted Therapyskin and connective tissue diseasesCells CulturedCell ProliferationMice KnockoutSystemic lupus erythematosusCell Deathbiologybusiness.industryInterleukinsMacrophagesGeneral MedicineMonocyte proliferationmedicine.diseaseLupus NephritisMice Inbred C57BLDisease Models AnimalBasic ResearchKidney Tubules030104 developmental biologyGene Expression RegulationNephrology030220 oncology & carcinogenesisImmunologyKnockout mouseDisease Progressionbiology.proteinChemokinesbusinessMacrophage proliferationNephritisJournal of the American Society of Nephrology
researchProduct

Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies.

2019

ObjectivesWe explored the impact of circulating anti-N-methyl-D-aspartate receptor (NMDAR) antibodies on the severity of fatigue in patients with systemic lupus erythematosus (SLE).MethodsSerum samples of 426 patients with SLE were analysed for the presence of antibodies to the NR2 subunit of the NMDAR. In parallel, the severity of fatigue was determined according to the Fatigue Scale for Motor and Cognitive functions questionnaire. In a subgroup of patients with SLE, the hippocampal volume was correlated with the levels of anti-NR2 antibodies. Isolated immunoglobulin G from patients with anti-NR2 antibodies were used for murine immunohistochemical experiments and functional assays on neuro…

AdultMaleAdolescentImmunologyEnzyme-Linked Immunosorbent AssayAntibodies Monoclonal HumanizedReceptors N-Methyl-D-AspartateSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunoglobulin GCell Line03 medical and health sciencesYoung Adult0302 clinical medicineCerebrospinal fluidRheumatologymedicineImmunology and AllergyHumansLupus Erythematosus SystemicReceptorFatigueAgedAutoantibodies030203 arthritis & rheumatologySystemic lupus erythematosusbiologybusiness.industryAutoantibodyMiddle Agedmedicine.diseaseBelimumabImmunologybiology.proteinImmunohistochemistryFemaleAntibodybusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugAnnals of the rheumatic diseases
researchProduct

Knockout of the KH-Type Splicing Regulatory Protein Drives Glomerulonephritis in MRL-Faslpr Mice

2021

KH-type splicing regulatory protein (KSRP) is an RNA-binding protein that promotes mRNA decay and thereby negatively regulates cytokine expression at the post-transcriptional level. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated cytokine expression causing multiple organ manifestations

MaleChemokineMice Inbred MRL lprQH301-705.5medicine.medical_treatmentLupus nephritisBiologyKidneyArticleImmune systemsystemic lupus erythematosusimmune system diseasesmedicinecytokineAnimalsCD11a AntigenRNA MessengerKSRPBiology (General)skin and connective tissue diseasesRegulation of gene expressionMice KnockoutSystemic lupus erythematosusFOXP3RNA-Binding ProteinsGlomerulonephritisGeneral Medicinemedicine.diseaseMice Inbred C57BLCytokineCancer researchbiology.proteinTrans-ActivatorsFemaleLymph NodesChemokinesBiomarkersglomerulonephritispost-transcriptional regulationCells
researchProduct

Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse a…

2017

B-cell activating factor of the tumour necrosis factor family (BAFF) is a cytokine, mainly produced by hematopoietic cells (e.g. monocytes/macrophages, dendritic cells), indispensable for B-cell maturation. The BLISS studies have demonstrated that blocking BAFF by the human monoclonal antibody belimumab is a valuable therapeutic approach in patients with clinically and serologically active systemic lupus erythematosus (SLE). However, the defined sources of BAFF, which contributes to SLE, are still unclear. Recent findings show that BAFF expression is not restricted to myeloid cells. Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study wa…

0301 basic medicineMalemedicine.medical_treatmentLupus nephritisAntibodies Monoclonal HumanizedKidneySeverity of Illness IndexPathogenesis03 medical and health sciencesMice0302 clinical medicinestomatognathic systemRheumatologyimmune system diseasesB-Cell Activating FactormedicineAnimalsHumansLupus Erythematosus Systemicskin and connective tissue diseasesB-cell activating factorAutocrine signallingRetrospective StudiesB-Lymphocytesbusiness.industryTumor Necrosis Factor-alphaEpithelial Cellsmedicine.diseaseBelimumabLupus Nephritisstomatognathic diseasesHaematopoiesis030104 developmental biologyCytokineReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologyCytokinesTumor necrosis factor alphaFemaleKidney DiseasesbusinessImmunosuppressive Agents030215 immunologymedicine.drugLupus
researchProduct

PS7:145 Il-34, not csf-1, similarly mediates rheumatoid and lupus arthritis in patients

2018

While Myeloid cells are abundant in lupus arthritis (LA) and rheumatoid arthritis (RA), based on clinical presentation LA and RA are considered distinct diseases. Although inflammatory arthritis is common in patients with lupus, the pivotal mechanisms leading to joint damage have not been investigated. We tested the hypothesis that IL-34, but not CSF-1, is a predictive biomarker that is integral in perpetuating synovial destructive inflammation in both LA and RA. We report the novel findings that: using longitudinally tracked patients, IL–34, not CSF–1, is a clinical predictive biomarker for both LA and RA; and IL–34 is more robustly expressed in the synovial tissue, cells and fluid compare…

ChemokineSystemic lupus erythematosusbiologybusiness.industryInflammatory arthritisArthritisInflammationmedicine.diseaseSynovial CellRheumatoid arthritisImmunologymedicinebiology.proteinBiomarker (medicine)medicine.symptombusinessPoster session 7: New drugs and trageted therapy
researchProduct

Lipid presentation by the protein C receptor links coagulation with autoimmunity.

2021

A lipid-protein autoimmunity target Several autoimmune diseases, including systemic lupus erythematosus and primary antiphospholipid syndrome, are characterized by the presence of antiphospholipid antibodies (aPLs). These molecules can activate the complement and coagulation cascades, which contributes to pathologies such as thrombosis, stroke, and pregnancy complications. Müller-Calleja et al. found that endothelial protein C receptor (EPCR) in complex with lysobisphosphatidic acid (LBPA) is the cell-surface target for aPL and mediates its internalization (see the Perspective by Kaplan). aPL binding to EPCR-LBPA resulted in the activation of tissue factor–mediated coagulation and interfero…

Receptor complexAntigen presentationAutoimmunityEndosomesmedicine.disease_causeArticleAutoimmunityMiceInterferonimmune system diseasesmedicineAnimalsHumansLupus Erythematosus SystemicneoplasmsBlood CoagulationAutoantibodiesAutoimmune diseaseEndothelial protein C receptorAntigen PresentationMultidisciplinaryInnate immune systemLupus erythematosusEndothelial Protein C ReceptorThrombosismedicine.diseaseAntiphospholipid SyndromeImmunity InnateMice Mutant StrainsDisease Models AnimalSphingomyelin PhosphodiesteraseToll-Like Receptor 7ImmunologyAntibodies AntiphospholipidEmbryo LossMonoglyceridesEndothelium VascularLysophospholipidsmedicine.drugScience (New York, N.Y.)
researchProduct

The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosi…

2020

Systemic lupus erythematosusMultiple Sclerosisbusiness.industryMultiple sclerosisImmunologyAutoantibodymedicine.diseaseImmunologyB-Cell Activating FactormedicineImmunology and AllergyNMDA receptorHumansLupus Erythematosus SystemicIn patientB-cell activating factorbusinessFatigueAutoantibodiesAutoimmunity reviews
researchProduct

The combination of chemotherapy and radiotherapy towards more efficient drug delivery.

2013

Research on anticancer therapies has advanced significantly in recent years. New therapeutic platforms that can further improve the health of patients are still highly demanded. We propose the idea of combining regular chemotherapy with radiation therapy to minimize side effects as well as increase drug-delivery efficiency. In this Focus Review, we seek to provide an overview of recent advances that can combine chemotherapy and radiotherapy. We begin by reviewing the current state of systems that can combine chemotherapy and gamma radiation. Among them, diselenide-containing polymers are highlighted as sensitive drug-delivery vehicles that can disassemble under gamma radiation. Then X-ray r…

medicine.medical_specialtyChemotherapyChemistrymedicine.medical_treatmentOrganic Chemistryfood and beveragesGeneral ChemistryChemoradiotherapyBiochemistryStimulus responseRadiation therapyDrug Delivery SystemsNeoplasmsDrug deliverymedicineHumansMedical physicsChemoradiotherapyChemistry, an Asian journal
researchProduct

P68 A diet rich in wheat alpha-amylase/trypsin inhibitors (ATIs) enhances disease progression in the MRL-Fas(lpr) mouse model of systemic lupus eryth…

2020

Background Wheat alpha-amylase/trypsin inhibitors (ATIs) are the second most prevalent proteins in wheat (3–4% vs 80–90% for gluten) and potent activators of the innate immune system via the toll like receptor 4 (TLR4)-MD2-CD14 complex in cells of the mononuclear phagocyte system (Junker Y et al, J Exp Med 2012), triggering several autoimmune/inflammatory diseases. In contrast, pure gluten that is de-enriched of ATIs shows no stimulatory activity. MRL-Fas(lpr) mice develop progressive and spontaneous glomerular, tubulointerstitial and perivascular kidney disease, arthritis, lymphadenopathy, splenomegaly and circulating autoantibodies in a syndrome that resembles systemic lupus erythematosus…

business.industryAutoantibodyArthritisSpleenInflammationMononuclear phagocyte systemurologic and male genital diseasesmedicine.diseaseProinflammatory cytokinemedicine.anatomical_structureimmune system diseasesImmunologymedicineTumor necrosis factor alphaHemoglobinuriamedicine.symptomskin and connective tissue diseasesbusinessPoster presentations
researchProduct

PS5:100 Patophysiological role of type i and iii interferons in systemic lupus erythematosus (sle)

2018

Systemic Lupus erythematosus (SLE) is an autoimmune disease characterised by activated autoreactive lymphocytes and autoantibodies, resulting in tissue damage in multiple organs. An important factor for the disease´s mortality is the development of Lupus nephritis (LN). Type I and III interferons, which are both part of the antiviral defense, have both been associated with the disease´s activity. In sera and urine of SLE patients an enhanced level of IL28/29 was described, but their distinct functional role in the course of disease need to be further investigated. To determine the role of type I and III interferons during onset and progression of autoimmunity – with focus on the development…

Autoimmune diseaseSystemic lupus erythematosusbusiness.industryLupus nephritisAutoantibodyGlomerulonephritisSpleenmedicine.diseasemedicine.disease_causeAutoimmunitymedicine.anatomical_structureimmune system diseasesImmunologyMedicineskin and connective tissue diseasesbusinessReceptorPoster session 5: Innate and adaptive immunity
researchProduct